Earnings Estimates Moving Higher for Pharming Group (PHAR): Time to Buy?

Core Viewpoint - Pharming Group N.V. Sponsored ADR (PHAR) shows a significant improvement in earnings outlook, making it an attractive investment option as analysts continue to raise earnings estimates for the company [1][2]. Earnings Estimates - Analysts' optimism regarding Pharming Group's earnings prospects is leading to higher estimates, which is expected to positively impact the stock price [2]. - The Zacks Rank system indicates a strong correlation between earnings estimate revisions and stock price movements, with Pharming Group benefiting from this trend [2][3]. Current-Quarter Estimates - For the current quarter, Pharming Group is expected to earn $0.03 per share, reflecting a year-over-year decline of 40.0% [6]. - Over the past 30 days, one estimate has increased with no negative revisions, resulting in a 150% increase in the Zacks Consensus Estimate [6]. Current-Year Estimates - For the full year, the expected earnings per share for Pharming Group is $0.06, representing a year-over-year increase of 137.5% [7]. - The trend for current-year estimate revisions is positive, with one estimate moving higher and no negative revisions, leading to a 220% increase in the consensus estimate [8]. Zacks Rank - The favorable estimate revisions have earned Pharming Group a Zacks Rank 1 (Strong Buy), indicating strong potential for outperformance [9]. - Research shows that stocks with a Zacks Rank 1 and 2 significantly outperform the S&P 500 [9]. Investment Outlook - Pharming Group's stock has risen 8.1% over the past four weeks due to strong estimate revisions, suggesting further upside potential [10]. - Investors may consider adding Pharming Group to their portfolios based on the current positive momentum [10].